Lilly aims to sell 15 new products in China; Roche's Xeloda gets EMEA nod for new use;

 @FiercePharma: Teva outgrows Big Pharma in IMS ranking. Report | Follow @FiercePharma

> In a streamlining effort, GSK centralizes security. Story

> Eli Lilly plans to launch 15 new products in China in the next five years, Chief Executive John Lechleiter has said. Report

> Roche says its blockbuster cancer drug Xeloda has been approved by the European Medicines Agency for treating patients with early colon cancer. Report

> GlaxoSmithKline has re-submitted its application to U.S. regulators for a new use of its Avodart drug in preventing prostate cancer. Report

> Pfizer has sued to prevent Teva Pharmaceutical Industries from selling a generic version of the Viagra impotence drug. Report

> The WHO has published guidance on the production of starting materials for active pharmaceutical ingredients, detailing recommendations to ensure product quality while keeping costs down. Report

Biotech News

 @FierceBiotech: "Wow": Developers prepare to reap rewards from biotech R&D tax credit. Story | Follow @FierceBiotech

 @JohnCFierce: Development is always a crap shoot. My one, absolute, gotta approve this year is Provenge. We'll see... | Follow @JohnCFierce

> GenVec shares implode on pancreatic cancer trial failure. Item

> Renamed Anchor in talks for $30M round, new pact. Report

> Medivation axes 20 percent of staff in follow-up to trial failure. Article

Manufacturing News

> Lilly unloads trials-supply business to Fisher Clinical. Story

> Regulators keep watch over KV, Acino operations. Report

> In streamlining effort, GSK centralizes security. Story

Biotech Research News

> Aura licenses new technology for guiding cancer drugs. Item

> Institutes break ground on San Diego stem cell 'collaboratory'. Report

> Gout therapy could lead to diabetes, obesity treatments. News

And Finally... A federal judge's ruling against gene patents could threaten the entire genetic research industry. Story

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.